Ovarian teratoid carcinosarcoma with a PIK3CA mutation: a case report and review of the literature.
OA: closed
Abstract
Ovarian teratoid carcinosarcoma involves an epithelial tumor of the Müllerian duct and an immature neuroepithelium, which is a characteristic of immature teratomas. Here, we describe the case of a 60-year-old woman who underwent surgery for a stage IC3 ovarian malignancy. The tumor showed a variety of histological features, including clear cell carcinoma, immature teratoma, and rhabdomyosarcoma, and a PIK3CA mutation was detected at the same locus in each. Two months after surgery and before the start of chemotherapy, multiple bone and liver metastases were found. Four courses of combination therapy with vincristine, actinomycin D and cyclophosphamide, the standard chemotherapy regimen for pediatric rhabdomyosarcoma, were administered, and a complete response was achieved. After a 2-month rest period, the patient developed recurrent peritoneal dissemination and underwent 6 courses of paclitaxel, carboplatin, and bevacizumab chemotherapy, resulting in a partial response. This is the eighth reported case of ovarian teratoid carcinosarcoma. This tumor has a very aggressive course, but initially responds to chemotherapy. However, survival over 5 years has not been reported, and elucidation of the pathogenesis and development of new treatment methods are needed.Supplementary informationThe online version contains supplementary material available at 10.1007/s13691-022-00571-w.
My notes (saved in your browser only)
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
SciLite annotations
chemicals 15
vincristine
actinomycin d
cyclophosphamide
paclitaxel
carboplatin
amlodipine
edoxaban
hydrate
vincristine
actinomycin d
cyclophosphamide
paclitaxel
carboplatin
pembrolizumab
aspartic acid
organisms 1
noordeloos 2009062
Source provenance
- europepmc
- last seen: 2026-07-23T06:14:19.317839+00:00
- scilite
- last seen: 2026-05-18T04:26:01.642840+00:00